PT  - JOURNAL ARTICLE
AU  - Maloney, Kevin M.
AU  - Driggers, Robert A.
AU  - Sarkar, Supriya
AU  - Anderson, Emeli
AU  - Malik, Amyn A.
AU  - Jenness, Samuel M.
TI  - Expanded Choices with Greater HIV Prevention Benefits: A Mathematical Model of Long-Acting Injectable and Daily-Oral Pre-Exposure Prophylaxis
AID  - 10.1101/19012443
DP  - 2019 Jan 01
TA  - medRxiv
PG  - 19012443
4099  - http://medrxiv.org/content/early/2019/11/22/19012443.short
4100  - http://medrxiv.org/content/early/2019/11/22/19012443.full
AB  - Objective To assess the population impact of long-acting injectable pre-exposure prophylaxis (LAI-PrEP) when available concurrently with daily oral (DO) PrEP among men who have sex with men (MSM).Design Dynamic network model of HIV transmission among MSM.Methods We calibrated our model to the current uptake of DO-PrEP (15% among indicated) and HIV prevalence (25.3%) among MSM in the southeastern US. Parameters for LAI-PrEP pharmacokinetics and efficacy were estimated from Phase IIa safety trials in human and macaque models. Primary analyses explored varied conditions of PrEP uptake and proportion choosing LAI-PrEP given initiation. Secondary analyses evaluated uncertainty in pharmacokinetic efficacy and in persistence to LAI-PrEP relative to DO-PrEP.Results If 50% of MSM currently accessing DO-PrEP choose LAI-PrEP when it becomes available, an additional 14.3% of infections could be averted over 10 years. If the availability of LAI-PrEP increased overall uptake of PrEP to 50%, the expected infections averted would increase to 23.9%. The benefit of LAI-PrEP was weakly sensitive to pharmacokinetics with 9.9% of infections averted even if LAI-PrEP efficacy were half of current empirical estimates. The superiority of LAI-PrEP was strongly attributable to better adherence and persistence with only 4.3% of infections averted if persistence were the same as DO-PrEP.Conclusions LAI-PrEP availability is projected to decrease HIV incidence. However, increased benefits depend upon improvements to adherence and persistence above current DO-PrEP levels. As LAI-PrEP becomes available, uptake and persistence should be monitored to ensure optimal implementation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by National Institutes of Health grants R21 MH112449, R01 AI138783, and P30 AI050409 (Emory University Center for AIDS Research).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis work was a simulation of disease transmission and does not represent analysis of primary data. The simulation parameters were derived from a variety of published data sources and referenced throughout the manuscript as necessary.